Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJEFFREY ZUBER, JAMES D. MCININCH, MARK K. SCHLEGEL, ADAM CASTORENO, LUCAS BONDURANT, DHAVAL OZA
Life of this patent
Estimating the term…
Abstract
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CIDEB gene, as well as methods of inhibiting expression of CIDEB, and methods of treating subjects that would benefit from reduction in expression of CIDEB, such as subjects having a CIDEB-associated disease, disorder, or condition, using such dsRNA compositions.
Claims37
(canceled)
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of cell death-inducing DFFA-like effector b (CIDEB) in a cell, wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein said antisense strand comprises a region of complementarity to an mRNA encoding CIDEB, and wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the antisense sequence,
- 5′-ACCGAGCUUAUAUUAGAUACUGA-3′ (SEQ ID NO:
- 1153).
(canceled)
(canceled)
-19. (canceled)
(canceled)
(canceled)
-117. (canceled)
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of cell death-inducing DFFA-like effector b (CIDEB) in a cell, wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand consists of the nucleotide sequence,
- (SEQ ID NO:
- 705)
- 5′-AGUAUCUAAUAUAAGCUCGGU-3′,
- and the antisense strand consists of the nucleotide sequence,
- SEQ ID NO:
- 1153
- 5′-ACCGAGCUUAUAUUAGAUACUGA-3′
- wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides;
- wherein the dsRNA agent is conjugated to a ligand at the 3′ end of the sense strand;
- and
- wherein the ligand is
A double stranded ribonucleic acid (dsRNA) agent comprising a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises the nucleotide sequence,
- 5′-asdCscgdAgdCuuaudAuUfagauacusgsa-3′ (SEQ ID. NO:
- 2049),
- wherein
- s is a phosphorothioate linkage;
- a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively;
- dA and cA are 2′-deoxy A and 2′-deoxy C, respectively;
- and
- Uf is 2′-deoxy-2′-fluoro (2′-F) U.
A double stranded ribonucleic acid (dsRNA) agent, or a pharmaceutically acceptable salt thereof, comprising a sense strand and an antisense strand forming a double stranded region, wherein the sense strand consists of the nucleotide sequence,
- 5′-asgsuaucuaAfUfAfuaagcucgguL96-3′ (SEQ ID. NO:
- 1601),
- and the antisense strand consists of the nucleotide sequence,
- 5′-asdCscgdAgdCuuaudAuUfagauacusgsa-3′ (SEQ ID. NO:
- 2049),
- wherein
- s is a phosphorothioate linkage;
- a, c, g, and u are 2′-O-methyl (2′-OMe) A, C, G, and U, respectively;
- dA and cA are 2′-deoxy A and 2′-deoxy C, respectively;
- and
- Af and Uf are 2′-deoxy-2′-fluoro (2′-F) A and U, respectively.
Dependencies are inferred from the claim text.